<p>Regeneron 的高管對 fianlimab + Libtayo 的潛力持樂觀態度；當研究未能產生預期結果時，股票開盤下跌超過 10%。</p>
<p>, /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) 的股東在 2026 年 5 月 16 日披露其 fianlimab + Libtayo 的 III 期黑色素瘤試驗未能達到主要終點後，股票大幅下跌，遭受了重大損失。投資者如果在 REGN 上虧損，鼓勵您現在提交信息以討論您的法律權利。您也可以通過電子郵件聯繫 Joseph E. Levi, Esq.，郵箱為 [email protected] 或撥打電話 (212) 363-7500。</p>
<p>在 2025 年 11 月和 12 月的醫療會議上，Regeneron 的高管積極強調其 LAG-3 研究的延遲，向投資者保證他們 “相信這是因為測試組表現良好。” Regeneron 投資者關係高級副總裁 Ryan Crowe 指出，這只是 “事件發生率的放緩”，同時向投資者確認管理層仍然 “對 fianlimab 加 Libtayo 能夠在當前治療標準中產生顯著差異充滿希望和信心。”</p>
<p>購買了 Regeneron 股票並遭受損失的股東被鼓勵點擊此處獲取有關 REGN 調查的更多信息。您也可以通過電子郵件聯繫 Joseph E. Levi, Esq.，郵箱為 [email protected] 或撥打電話 (212) 363-7500。</p>
<p>Levi &amp; Korsinsky, LLP -- 前 50 大證券訴訟公司（ISS，連續七年）。超過 70 名專業人士。已追回數億資金。</p>
<p>關於 REGN 調查的常見問題</p>
<p><strong>問：誰有資格參與 REGN 調查？</strong> 答：購買了 REGN 股票或證券並遭受財務損失的投資者可能有資格。資格基於購買日期和記錄的損失，而不是您是否仍持有股票。</p>
<p><strong>問：哪些聲明被調查為可能具有誤導性？</strong> 答：調查涉及 Regeneron Pharmaceuticals 是否就其 III 期黑色素瘤試驗的潛力和進展做出了實質性虛假或誤導性陳述。當試驗失敗被揭露時，股價急劇下跌。</p>
<p><strong>問：REGN 投資者現在需要做什麼？</strong> 答：收集經紀記錄，包括購買日期、股票數量和支付價格。聯繫 Levi &amp; Korsinsky 進行免費的無義務評估，郵箱為 [email protected] 或撥打電話 (212) 363-7500。無需立即採取行動以保持參與調查的資格。</p>
<p><strong>問：我聯繫 Levi &amp; Korsinsky 後會發生什麼？</strong> 答：律師將免費審查您的交易歷史，並提供您潛在賠償的初步評估。</p>
<p><strong>問：如果我已經出售了我的 REGN 股票 -- 我還可以追回損失嗎？</strong> 答：可以。資格基於您購買的時間，而不是您是否仍持有股票。購買了 REGN 並以虧損出售的投資者仍然可以參與調查。</p>
<p><strong>問：我需要去法庭或作證嗎？</strong> 答：不需要。參與調查不需要出庭或作證。如果後續採取法律行動，絕大多數受影響的投資者也不需要出庭。</p>
<p><strong>問：參與需要我支付什麼費用嗎？</strong> 答：不需要。證券調查及任何後續行動均以純粹的風險代理方式進行。沒有前期費用，沒有保留金，沒有自付費用。</p>
<p>聯繫方式：\</p>
<p>Levi &amp; Korsinsky, LLP\</p>
<p>Joseph E. Levi, Esq.\</p>
<p>Ed Korsinsky, Esq.\</p>
<p>33 Whitehall Street, 27th Floor\</p>
<p>New York, NY 10004\</p>
<p>[email protected]\</p>
<p>電話: (212) 363-7500\</p>
<p>傳真: (212) 363-7171</p>
<p>來源 Levi &amp; Korsinsky, LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE4Jk5ld3NJdGVtSWQ9Tlk2MjI1MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTgxODI0UFJfTkVXU19VU1BSX19fX19OWTYyMjUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE4Jk5ld3NJdGVtSWQ9Tlk2MjI1MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTgxODI0UFJfTkVXU19VU1BSX19fX19OWTYyMjUw"/></p>

再生元制藥

基因改革 ETF - ARK

醫療業 ETF - Vanguard

<p>Levi & Korsinsky 正在調查再生元製藥（Regeneron Pharmaceuticals，REGN），因其在 fianlimab + Libtayo 的 III 期黑色素瘤試驗失敗後，股票遭遇重大損失。該股票在試驗未能達到主要終點後下跌超過 10%。遭受損失的股東被鼓勵聯繫該公司以尋求潛在的法律救濟</p>

<p><em>Regeneron's executives were optimistic about the potential for fianlimab + Libtayo; when the study failed to produce exepected results, the stock opened down more than 10%.</em></p>
<div class="lb-trans"><p>Regeneron 的高管對 fianlimab + Libtayo 的潛力持樂觀態度；當研究未能產生預期結果時，股票開盤下跌超過 10%。</p>
</div><p>, /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) shareholders saw significant losses when the stock dropped sharply following the May 16, 2026 disclosure that its Phase 3 melanoma trial of fianlimab + Libtayo failed to meet its primary endpoint versus Keytruda. Investors who lost money on REGN are encouraged to submit their information now to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) 的股東在 2026 年 5 月 16 日披露其 fianlimab + Libtayo 的 III 期黑色素瘤試驗未能達到主要終點後，股票大幅下跌，遭受了重大損失。投資者如果在 REGN 上虧損，鼓勵您現在提交信息以討論您的法律權利。您也可以通過電子郵件聯繫 Joseph E. Levi, Esq.，郵箱為 [email protected] 或撥打電話 (212) 363-7500。</p>
</div><p>During healthcare conference presentations in November and December of 2025, Regeneron executives positively highlighted a delay to its LAG-3 study, assuring investors they &#34;believe this is because the test arms are performing well.&#34; Regeneron's Senior Vice President of Investor Relations, Ryan Crowe, noted it was just a mere &#34;slowing of event rates&#34; while confirming to investors management still had &#34;a lot of hope and confidence that fianlimab-plus Libtayo can generate a meaningful differentiation against current standards of care.&#34;</p>
<div class="lb-trans"><p>在 2025 年 11 月和 12 月的醫療會議上，Regeneron 的高管積極強調其 LAG-3 研究的延遲，向投資者保證他們 “相信這是因為測試組表現良好。” Regeneron 投資者關係高級副總裁 Ryan Crowe 指出，這只是 “事件發生率的放緩”，同時向投資者確認管理層仍然 “對 fianlimab 加 Libtayo 能夠在當前治療標準中產生顯著差異充滿希望和信心。”</p>
</div><p>Shareholders who purchased Regeneron stock and suffered a loss are encouraged to click here to get more information about the REGN investigation. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.</p>
<div class="lb-trans"><p>購買了 Regeneron 股票並遭受損失的股東被鼓勵點擊此處獲取有關 REGN 調查的更多信息。您也可以通過電子郵件聯繫 Joseph E. Levi, Esq.，郵箱為 [email protected] 或撥打電話 (212) 363-7500。</p>
</div><p>Levi &amp; Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP -- 前 50 大證券訴訟公司（ISS，連續七年）。超過 70 名專業人士。已追回數億資金。</p>
</div><p>Frequently Asked Questions About the REGN Investigation</p>
<div class="lb-trans"><p>關於 REGN 調查的常見問題</p>
</div><p><strong>Q: Who is eligible to participate in the REGN investigation?</strong> A: Investors who purchased REGN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.</p>
<div class="lb-trans"><p><strong>問：誰有資格參與 REGN 調查？</strong> 答：購買了 REGN 股票或證券並遭受財務損失的投資者可能有資格。資格基於購買日期和記錄的損失，而不是您是否仍持有股票。</p>
</div><p><strong>Q: Which statements are being investigated as potentially misleading?</strong> A: The investigation concerns whether Regeneron Pharmaceuticals made materially false or misleading statements regarding the potential and progress of its Phase 3 melanoma trial. When the trial failure was revealed, the stock price declined sharply.</p>
<div class="lb-trans"><p><strong>問：哪些聲明被調查為可能具有誤導性？</strong> 答：調查涉及 Regeneron Pharmaceuticals 是否就其 III 期黑色素瘤試驗的潛力和進展做出了實質性虛假或誤導性陳述。當試驗失敗被揭露時，股價急劇下跌。</p>
</div><p><strong>Q: What do REGN investors need to do right now?</strong> A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi &amp; Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.</p>
<div class="lb-trans"><p><strong>問：REGN 投資者現在需要做什麼？</strong> 答：收集經紀記錄，包括購買日期、股票數量和支付價格。聯繫 Levi &amp; Korsinsky 進行免費的無義務評估，郵箱為 [email protected] 或撥打電話 (212) 363-7500。無需立即採取行動以保持參與調查的資格。</p>
</div><p><strong>Q: What happens after I contact Levi &amp; Korsinsky?</strong> A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.</p>
<div class="lb-trans"><p><strong>問：我聯繫 Levi &amp; Korsinsky 後會發生什麼？</strong> 答：律師將免費審查您的交易歷史，並提供您潛在賠償的初步評估。</p>
</div><p><strong>Q: What if I already sold my REGN shares -- can I still recover losses?</strong> A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought REGN and sold at a loss may still participate in the investigation.</p>
<div class="lb-trans"><p><strong>問：如果我已經出售了我的 REGN 股票 -- 我還可以追回損失嗎？</strong> 答：可以。資格基於您購買的時間，而不是您是否仍持有股票。購買了 REGN 並以虧損出售的投資者仍然可以參與調查。</p>
</div><p><strong>Q: Do I need to go to court or give testimony?</strong> A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.</p>
<div class="lb-trans"><p><strong>問：我需要去法庭或作證嗎？</strong> 答：不需要。參與調查不需要出庭或作證。如果後續採取法律行動，絕大多數受影響的投資者也不需要出庭。</p>
</div><p><strong>Q: What does it cost me to participate?</strong> A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.</p>
<div class="lb-trans"><p><strong>問：參與需要我支付什麼費用嗎？</strong> 答：不需要。證券調查及任何後續行動均以純粹的風險代理方式進行。沒有前期費用，沒有保留金，沒有自付費用。</p>
</div><p>CONTACT:\</p>
<div class="lb-trans"><p>聯繫方式：\</p>
</div><p>Levi &amp; Korsinsky, LLP\</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP\</p>
</div><p>Joseph E. Levi, Esq.\</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.\</p>
</div><p>Ed Korsinsky, Esq.\</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.\</p>
</div><p>33 Whitehall Street, 27th Floor\</p>
<div class="lb-trans"><p>33 Whitehall Street, 27th Floor\</p>
</div><p>New York, NY 10004\</p>
<div class="lb-trans"><p>New York, NY 10004\</p>
</div><p>[email protected]\</p>
<div class="lb-trans"><p>[email protected]\</p>
</div><p>Tel: (212) 363-7500\</p>
<div class="lb-trans"><p>電話: (212) 363-7500\</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>傳真: (212) 363-7171</p>
</div><p>SOURCE Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>來源 Levi &amp; Korsinsky, LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE4Jk5ld3NJdGVtSWQ9Tlk2MjI1MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTgxODI0UFJfTkVXU19VU1BSX19fX19OWTYyMjUw" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY62250&amp;Transmission_Id=202605181824PR_NEWS_USPR_____NY62250&amp;DateId=20260518"/></p>

18:24 ETRegeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)

prnewswire

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

美國制藥 ETF - iShares

標普生物技術 3 倍做多 - Direxion

標普生物技術 3 倍做空 - Direxion

紐交所高增長板生物技術指數 ETF - First Trust

Invesco Nasdaq Biotechnology ETF

18:24 ET 再生元製藥調查啓動：Levi & Korsinsky 對再生元製藥（REGN）的高管和董事進行調查